Oncology Venture announced on 4 September 2019 that it has appointed a new CEO, Steve Carchedi, former senior executive of J&J and Mallinckrodt. This comes at a critical juncture for the company as it moves its programmes into the late stage and starts to look for development partners to advance these assets. The company has made substantial progress getting LiPlaCis ready to launch Phase III studies with IND and IDE applications.
13 Sep 2019
Oncology Venture - New CEO as company moves toward late stage
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Oncology Venture - New CEO as company moves toward late stage
- Published:
13 Sep 2019 -
Author:
Dr Nathaniel Calloway -
Pages:
6
Oncology Venture announced on 4 September 2019 that it has appointed a new CEO, Steve Carchedi, former senior executive of J&J and Mallinckrodt. This comes at a critical juncture for the company as it moves its programmes into the late stage and starts to look for development partners to advance these assets. The company has made substantial progress getting LiPlaCis ready to launch Phase III studies with IND and IDE applications.